Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD

(4502)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Rosen Law Firm Announces Investigation of Securities Claims Against Takeda Pharmaceutical Company Limited – TAK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 06:04pm EDT

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Takeda Pharmaceutical Company Limited (NYSE: TAK) resulting from allegations that Takeda may have issued materially misleading business information to the investing public.

On May 14, 2019, Takeda forecasted an unexpected operating loss for the current year, citing costs associated with Takeda’s $59 billion purchase of Shire Plc. On this news, Takeda’s securities fell $1.57 per share, or over 8%, to close at $17.92 on May 14, 2019.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Takeda investors. If you purchased shares of Takeda please visit the firm’s website at http://www.rosenlegal.com/cases-register-1610.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TAKEDA PHARMACEUTICAL CO L
07/18GLOBAL MARKETS LIVE : Microsoft, Qualcomm, Netflix, Facebook…
07/17Takeda kicks off sale of Western European drugs - sources
RE
07/16TAKEDA PHARMACEUTICAL : First iPSC-Derived CAR T-Cell Therapy Created by Kyoto U..
PU
07/09TAKEDA PHARMACEUTICAL : Continues Ongoing Inclusion in the FTSE4Good Developed I..
PU
07/09TAKEDA PHARMACEUTICAL : EIP Pharma Appoints Noel Donnelly as CFO
AQ
07/08TAKEDA PHARMACEUTICAL : Unveils New Data from the PROPEL Study at ISTH 2019, Rei..
AQ
07/08TAKEDA PHARMACEUTICAL : Ireland celebrates opening of new innovative manufacturi..
AQ
07/08TAKEDA PHARMACEUTICAL : Unveil New Data from the PROPEL Study at ISTH 2019, Rein..
BU
07/03TAKEDA PHARMACEUTICAL : Announces Baxalta's Successful Consent Solicitation with..
AQ
07/03ALEMBIC : Pharmaceuticals receives USFDA Approval for Febuxostat Tablets, 40 mg ..
AQ
More news
Financials (JPY)
Sales 2020 3 344 B
EBIT 2020 -35 925 M
Net income 2020 -188 602 M
Debt 2020 4 455 B
Yield 2020 4,81%
P/E ratio 2020 -48,5x
P/E ratio 2021 22,3x
EV / Sales2020 3,09x
EV / Sales2021 2,90x
Capitalization 5 867 B
Chart TAKEDA PHARMACEUTICAL CO LTD
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 5 395,45  JPY
Last Close Price 3 746,00  JPY
Spread / Highest target 68,2%
Spread / Average Target 44,0%
Spread / Lowest Target 20,1%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD3.48%54 460
JOHNSON & JOHNSON2.34%345 980
PFIZER-1.35%237 451
ROCHE HOLDING LTD.11.42%230 263
ROCHE HOLDING13.37%230 263
NOVARTIS24.46%216 273